10年前，《来自星星的你》、《想你》等韩剧热播，以及少女时代、东方神起等韩国男女团席卷东南亚。得益于这股热潮，韩流也带动LG生活健康、爱 茉莉太平洋、爱敬、珂莱欧等老牌化妆品巨头走向海外市场(尤其中国)。 时移势易，老牌韩妆巨头深陷增长周期低迷，新一代新锐品牌则凭借科技赋能与精准营销成功开拓美国市场，成为行业新晋崛起力量。 连涨11年，这一韩妆新贵利润超LG 此前，于2025年11月以97967亿韩元(约合人民币478.18亿元)登顶韩妆市值榜首的APR公司，在今日(2月4日)正式发布其2025年及该年第四季度财报。 财报显示，APR公司2025年业绩呈三位数激增，其销售额为15273.45亿韩元(约合人民币73.31亿元)，同比大涨111.3%；营业利润则暴增197.8%至3653.71 亿韩元(约合人民币17.54亿元)；营业利润率则上涨6.9个百分比至24%。 | Unit : KRW Mn, % | | | Quarter | | | Note | | --- | --- | --- | --- | --- | --- | --- | | | 4Q24 % of | | 4Q25 | % of | Y ...

记者今天（5日）从国家药监局获悉，2025年国家化妆品抽样检验发现，50批次化妆品不符合 规定，包括标称为俏因子草本清肌泥膜粉，菌落总数、霉菌和酵母菌总数超出规定要求；标称 为香雪兰强力去屑蓬松柔软洗发乳，检测发现丙烯酰胺含量超出规定要求；标称为优佳隔离多 效亮肤防晒乳SPF50+ PA++++（瑞士进口），在成分对比项目中，发现检出产品标签及注册 资料载明的技术要求未标示的防晒剂对甲氧基肉桂酸异戊酯；未检出产品标签及注册资料载明 的技术要求标示的防晒剂：水杨酸乙基己酯、乙基己基三嗪酮、亚甲基双-苯并三唑基四甲基 丁基酚、双-乙基己氧苯酚甲氧苯基三嗪等，不符合产品检出成分、产品标签应当与该产品注 册资料载明的技术要求一致的要求。 国家药监局目前根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》《化妆品抽样 检验管理办法》，要求浙江、广东、青海省药品监督管理部门对上述不符合规定化妆品涉及的 注册人、备案人、受托生产企业等依法立案调查，责令相关企业依法采取风险控制措施并开展 自查整改。各省级药品监督管理部门要依法责令相关化妆品经营者停止经营上述化妆品，并依 法调查其进货查验记录等情况，对违法产品进行追根溯源 ...

公开资料显示，菌落总数是指在一定条件下每克（每毫升）检样所生长出来的细菌菌落总数，表示着产品受细菌 污染的程度，是关系到产品质量和消费者健康、安全的重要指标。使用菌落总数超标的化妆品，如果皮肤上有微 小的伤口便可能引起感染或炎症。 新京报贝壳财经讯（记者李铮）2月5日，新京报贝壳财经记者从国家药品监督管理局官网获悉，在2025年国家化 妆品抽样检验工作中，经贵州省食品药品检验所等单位检验，共有50批次化妆品不符合规定，涉及俏因子、康之 本、维她丽等品牌，涵盖护发素、洗发乳、祛斑霜、防晒乳等品类。 进一步查看不符合规定的化妆品信息，记者注意到，菌落总数超标、成分比对项目不符合规定，成为"重灾区"。 其中，共有7批次化妆品的菌落总数超标，占比约14%。 | | | | 费州省遭 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 义市汇川 | | | | | | | | | | | | | | 广州市花都区花 | 区流可避 | | | ...

经济观察网 据央视新闻2月5日消息，国家药监局表示，2025年国家化妆品抽样检验发现，50批次化妆 品不符合规定，包括标称为俏因子草本清肌泥膜粉，菌落总数、霉菌和酵母菌总数超出规定要求；标称 为香雪兰强力去屑蓬松柔软洗发乳，检测发现丙烯酰胺含量超出规定要求；标称为优佳隔离多效亮肤防 晒乳SPF50+ PA++++（瑞士进口），在成分对比项目中，发现检出产品标签及注册资料载明的技术要求 未标示的防晒剂对甲氧基肉桂酸异戊酯；未检出产品标签及注册资料载明的技术要求标示的防晒剂：水 杨酸乙基己酯、乙基己基三嗪酮、亚甲基双-苯并三唑基四甲基丁基酚、双-乙基己氧苯酚甲氧苯基三嗪 等，不符合产品检出成分、产品标签应当与该产品注册资料载明的技术要求一致的要求。 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of the medical beauty and cosmetics sectors, with significant growth potential driven by consumer demand for emotional value and safety in products [8][50] - Key companies in the medical beauty sector include Meili Tianyuan Medical Health, which is expanding through acquisitions and strong operational strategies, and in the cosmetics sector, brands like HBN and Banmu Huatian are leading with innovative product offerings and market strategies [8][24][34] Summary by Sections Market Review - The beauty and personal care index rose by 0.44% in January, ranking 24th among all sectors, underperforming the overall market [14][15] - Notable stock performances in January included SiHuan Pharmaceutical (+28.5%) and Yonghe Medical (+22.7%) in the medical beauty sector, while Yiwan Yichuang (+50.8%) and Ruoyu Chen (+8.1%) led in cosmetics [5][15] Medical Beauty - The approval of a new composite solution by Juzhi Biotechnology marks a significant advancement in the field, showcasing the company's R&D capabilities [6][19] - Meili Tianyuan announced a positive earnings forecast, projecting revenues of at least 3 billion yuan for 2025, reflecting a growth of over 16% year-on-year [22] Cosmetics - Banmu Huatian's parent company has filed for an IPO, aiming to leverage its strong market position in body care products [24] - HBN, a leading domestic skincare brand, has also submitted its IPO application, highlighting its innovative product lines and strong sales performance [34] Investment Recommendations - The report recommends focusing on high-quality companies in the medical beauty and cosmetics sectors that cater to emotional consumption trends, with specific mentions of Meili Tianyuan, Aimeike, and Ruoyu Chen among others [8][49] - In cosmetics, brands like Maogeping and Porlaia are highlighted for their strong market positions and innovative strategies [50][52]

（文章来源：央视新闻） 国家药监局目前根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》《化妆品抽样检验管理 办法》，要求浙江、广东、青海省药品监督管理部门对上述不符合规定化妆品涉及的注册人、备案人、 受托生产企业等依法立案调查，责令相关企业依法采取风险控制措施并开展自查整改。各省级药品监督 管理部门要依法责令相关化妆品经营者停止经营上述化妆品，并依法调查其进货查验记录等情况，对违 法产品进行追根溯源，发现违法行为的，依法严肃查处；涉嫌犯罪的，依法移送公安机关。 记者今天（5日）从国家药监局获悉，2025年国家化妆品抽样检验发现，50批次化妆品不符合规定，包 括标称为俏因子草本清肌泥膜粉，菌落总数、霉菌和酵母菌总数超出规定要求；标称为香雪兰强力去屑 蓬松柔软洗发乳，检测发现丙烯酰胺含量超出规定要求；标称为优佳隔离多效亮肤防晒乳SPF50+ PA++++（瑞士进口），在成分对比项目中，发现检出产品标签及注册资料载明的技术要求未标示的防 晒剂对甲氧基肉桂酸异戊酯；未检出产品标签及注册资料载明的技术要求标示的防晒剂：水杨酸乙基己 酯、乙基己基三嗪酮、亚甲基双-苯并三唑基四甲基丁基酚、双-乙基己氧苯酚甲氧苯基三 ...

Group 1 - The stock of Giant Bio (02367.HK) increased by over 8% during the trading session, with a current rise of 7.03% to HKD 34.4 [1] - The trading volume reached HKD 256 million [1]

Group 1 - The new consumption concept in Hong Kong stocks is showing active performance, with notable increases in companies such as Giant Bio (+5.54%), Mao Geping (+4.42%), Miniso (+3.92%), and Pop Mart (+3.79%) [2][3] - The State Council has issued a plan to accelerate the cultivation of new growth points in service consumption, focusing on enhancing key areas such as transportation, housekeeping, online audio-visual services, and inbound consumption [2][4] Group 2 - Pop Mart's new product series, PUCKY and Starry People, have gained significant popularity, with market estimates suggesting that the valuation of Pop Mart's IP potential is still underestimated [5] - Recent trends indicate that Pop Mart's new products are selling out on official websites and commanding high premiums on second-hand platforms, with hidden versions priced at 2-3 times and 3-6 times their original prices [5] - The cosmetics industry is projected to grow, with a retail sales increase of 6.18% year-on-year in 2023, as consumer spending stabilizes and the demand for product upgrades continues [5] Group 3 - The channel landscape is showing differentiated characteristics, with platforms like Douyin leading in sales and Tmall achieving its best growth in four years during the Double Eleven shopping festival [6] - Local brands are steadily increasing their market share, although market differentiation is intensifying, with companies like Anta, Pop Mart, and Haidilao identified as industry favorites for optional consumption [6][7] - Five major investment themes have been identified for 2026, focusing on emotional value consumption, health and wellness needs, the silver economy, emerging channel penetration, and multi-brand strategies [7]

格隆汇2月5日｜美国化妆品公司e.l.f. Beauty公布2026财年第三季度业绩，净销售额同比增长38%至4.9亿 美元，高于市场预期的4.6亿美元，主要得益于零售商和电子商务渠道的增长；经调整每股盈利1.24美 元，远超市场预期的0.72美元。展望2026财年，公司提高业绩指引，预计营收将介于16亿至16.1亿美元 之间，调整后每股收益将介于3.05至3.10美元之间，对比市场预期分别为15.7亿和2.87美元。 ...

Core Insights - In 2025, Shaanxi aims to enhance law enforcement collaboration across provincial and municipal levels, targeting 2,678 cases related to "two products and one device" (drugs, cosmetics, and medical devices) and transferring 56 cases to judicial authorities [1] Group 1: Regulatory Focus - Shaanxi's regulatory efforts have concentrated on high-risk enterprises, high-risk products, and critical production processes, ensuring compliance with drug quality management standards [1] - The province has implemented a "rectification follow-up" mechanism to track the compliance of enterprises with corrective actions [1] Group 2: Online Sales Regulation - To address challenges posed by online drug sales, Shaanxi has strengthened integrated supervision of online and offline sales, emphasizing corporate responsibility [1] - The province is focusing on cracking down on illegal online drug sales, including unqualified sales and prescription drugs sold without prescriptions [1] Group 3: Regulatory Efficiency - Shaanxi is promoting service-oriented law enforcement in drug regulation, allowing for leniency in minor violations through a "first violation not penalized" list [1] - The province is also piloting reforms to optimize the review and approval process for supplementary drug applications [1] Group 4: Future Initiatives - Shaanxi plans to enhance high-level regulation throughout the drug lifecycle, continuing initiatives such as the "clean source" action in drug operations and a three-year improvement plan for cosmetic production quality management systems [2]